|
THURSDAY, June 21, 2007
Session 1: OPENING SESSION (h. 13.30 - 15.25) |
| hour: |
|
|
abstract page ref.: |
| 13.30-13.50 |
Opening
Remarks |
Rainer
Dietz (Berlin, Germany)
Valentin Fuster (New York, NY, USA)
Rodolfo Paoletti (Milan, Italy) |
– |
| 13.50-14.30 |
Opening
Lecture
INTEGRATION OF BIOIMAGING AND BIOCHEMICAL MARKERS
IN THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE:
STATE OF THE ART, OPEN QUESTIONS AND PROPOSALS |
Valentin Fuster (New York, NY, USA) |
– |
| 14.30-14.45 |
LEGACY
OF THE 1ST AND PRESENTATION OF THE 2ND SYMPOSIUM |
Santica M.
Marcovina (Seattle, WA, USA) |
– |
| 14.45-15.05 |
BIOCHEMICAL
MARKERS: STATE OF THE ART. QUALITY ASSURING CARDIAC BIOMARKERS
TO FACILITATE CORRELATIONS WITH IMAGING |
Allan S. Jaffe
(Rochester, MN, USA) |
19 |
| 15.05-15.25 |
BIOIMAGING
MARKERS: STATE OF THE ART |
Jean-Claude
Tardif (Montreal, Canada) |
19 |
| 15.25 |
End
of the Session |
|
|
| 15.25-15.45 |
Coffee
Break |
|
|
Session 2: PRESENTATION OF CLINICAL CASES
(h. 15.45 - 18.45)
|
Purpose of this session: practical
presentation of selected clinical cases, recorded
in the Charitè Cardiology Department prior
to the Symposium, to highlight open questions, critical
issues, verified usefulness, and effectiveness of
the use of integrated bioimaging and biochemical markers
in the clinical decision-making.
Stroke
Chairs:
Jan Sobesky (Cologne, Germany)
Arno Villringer (Berlin, Germany)
|
| hour: |
|
|
abstract
page ref.: |
| 15.45-16.15 |
USE
OF INTEGRATED BIOMARKERS IN STROKE: STATE OF THE ART |
Jan Sobesky
(Cologne, Germany)
|
19 |
| 16.15-16.30 |
ACUTE
ISCHEMIC STROKE |
Gerhard J.
Jungehülsing (Berlin, Germany) |
- |
| 16.30-16.45 |
Panel
discussion |
|
|
| 16.45-17.00 |
CHRONIC
CEREBRAL ISCHEMIA |
Christian
H. Nolte (Berlin, Germany) |
20 |
| 17.00-17.15 |
Panel
discussion |
|
|
| 17.15-17.35 |
General
Discussion |
|
|
| hour: |
|
|
abstract
page ref.: |
| 17.35-18.05 |
USE
OF INTEGRATED BIOMARKERS IN PULMONARY EMBOLISM: STATE
OF THE ART |
Evangelos
Giannitsis (Heidelberg, Germany) |
|
| 18.05-18.20 |
ACUTE
PULMONARY EMBOLISM |
Jörn
Vollert (Berlin, Germany)
|
|
| 18.20-18.35 |
Panel
discussion |
|
|
| 18.35-18.45 |
General
Discussion |
|
|
| 18.45 |
End
of the Session |
|
|
| 18.45 |
Poster
visit and reception |
|
|
TOP
FRIDAY, June 22, 2007
Session 3: PRESENTATION OF CLINICAL CASES
(h. 8.30 - 13.00)
|
Purpose of this session: practical presentation of
selected clinical cases, recorded in the Charitè
Cardiology Department prior to the Symposium, to highlight
open questions, critical issues, verified usefulness,
and effectiveness of the use of integrated bioimaging
and biochemical markers in the clinical decision-making.
Acute
Chest Pain
Chairs:
Rainer
Dietz (Berlin,
Germany)
Jean-Claude Tardif (Montreal, QC, Canada)
|
| hour: |
|
|
abstract
page ref.: |
| 8.30-9.30 |
USE
OF INTEGRATED BIOMARKERS IN ACUTE CHEST PAIN
State of the Art Lectures |
W. Frank Peacock
(Cleveland, OH, USA)
Frank H. Wians, Jr. (Dallas, TX, USA)
Martin Möckel (Berlin, Germany)
|
21
21
22 |
| 9.30-9.45 |
TYPICAL
ACUTE CORONARY SYNDROME |
Malte Schröder
(Berlin, Germany) |
22 |
| 9.45-10.00 |
Panel
discussion |
|
|
| 10.00-10.15 |
ACUTE
HEART ATTACK |
Martin Möckel
(Berlin, Germany) |
- |
| 10.15-10.30 |
Panel
Discussion |
|
|
| 10.30-10.45 |
General
Discussion |
|
|
| 10.45-11.05 |
Coffee
Break |
|
|
Inflammatory
Disease of the Heart
Chairs:
Wilhelm Haverkamp (Berlin, Germany)
Juan Carlos Kaski (London, UK)
|
| hour: |
|
|
abstract
page ref.: |
| 11.05-11.45 |
USE
OF INTEGRATED BIOMARKERS IN INFLAMMATORY DISEASE
OF THE HEART
State of the Art Lectures: |
USE OF
IMMUNOLOGICAL BIOMARKERS IN INFLAMMATORY CARDIOMYOPATHY
Bernhard Maisch (Marburg, Germany)
INFLAMMATORY DISEASE.
NON INVASIVE IMAGING CARDIOVASCULAR MAGNETIC RESONANCE
Jeanette Schulz-Menger, Hassan
Abdel-Aty (Berlin, Germany)
|
23
23 |
| 11.45-12.00 |
MYOCARDIAL
INVOLVEMENT IN SYSTEMIC DISORDER |
Ralf
Wassmuth
(Berlin, Germany) |
24 |
| 12.00-12.15 |
Panel
discussion |
|
|
| 12.15-12.30 |
MYOCARDITIS:
A CASE OF A 55-YEAR-OLD MAN WITH MYOCARDITIS DIAGNOSIS
USING CARDIAC MAGNETIC RESONANCE IMAGING |
Andre
Rudolph, Jeanette Schulz-Menger (Berlin,
Germany) |
24 |
| 12.30-12.45 |
Panel
Discussion |
|
|
| 12.45-13.00 |
General
Discussion |
|
|
| 13.00 |
Coffee
Break |
|
|
| 13.00-14.15 |
Lunch
and Poster Discussion |
|
|
|
Session 4: THE ROAD TO THE INTEGRATED BIOMARKER
APPROACH IN PRIMARY
AND SECONDARY PREVENTION AND IN TREATMENT MONITORING
(h. 14.15 - 18.15)
|
Purpose of this session: to present
the method and tools to support clinical decision-making
through an integrated approach
Chairs:
John J. Albers (Seattle, WA, USA)
Michael E. Mendelsohn (Boston, MA,
USA)
The
Integrated Approach: Added Value
|
| hour: |
|
|
abstract
page ref.: |
| 14.15-14.35 |
THE
INTEGRATED BIOMARKER APPROACH: ADDED VALUE IN
PRIMARY AND SECONDARY PREVENTION? |
Wolfgang
Koenig (Ulm, Germany)
|
25 |
| 14.35-14.45 |
Discussion |
|
|
| 14.45-15.05 |
BIOMARKERS
OF INFLAMMATION AS MARKERS OF TREATMENT OUTCOME |
Juan
Carlos Kaski (London, UK) |
25 |
| 15.05-15.15 |
Discussion |
|
|
| 15.15-15.35 |
ROLE
OF BIOMARKERS IN ATHEROSCLEROSIS |
Udo
Seedorf (Münster, Germany) |
26 |
| 15.35-15.45 |
Discussion |
|
|
| 15.45-16.05 |
Coffee
Break |
|
|
The Integrated Approach: Critical Issues
|
| hour: |
|
|
abstract
page ref.: |
| 16.05-16.35 |
ANALYSIS
OF MULTIPLE BIOMARKERS: THE USE OF LOGISTIC REGRESSION
AND CLASSIFICATION TREES (CART) |
Reinhold
Mueller (Townsville, Australia)
|
26 |
| 16.35-16.45 |
Discussion |
|
|
| 16.45-17.05 |
DIAGNOSTIC
AND THERAPEUTIC POTENTIAL OF BIOMARKERS FOR GENDER-SPECIFIC
ASPECTS OF CVD |
Michael
E. Mendelsohn (Boston, MA, USA) |
26 |
| 17.05-17.15 |
Discussion |
|
|
| 17.15-17.35 |
METHODOLOGICAL
REQUIREMENTS FOR INTEGRATION OF MULTIMARKER ANALYSIS |
Alan
H.B. Wu (San Francisco, CA, USA) |
27 |
| 17.35-17.45 |
Discussion |
|
|
| 17.45-18.05 |
ASSESSING
LDL LOWERING THERAPY |
Allan
D. Sniderman (Montreal, QC, Canada) |
27 |
| 18.05 -18.15 |
Discussion |
|
|
| 18.15 |
End
of the Session |
|
|
| 18.15-19.00 |
Poster
visit |
|
|
TOP
SATURDAY, June 23, 2007
Session 5: QUALIFICATION OF INTEGRATED BIOMARKERS
(h. 8.30 - 13.00)
|
Purpose of this session: to discuss
the main issues and obstacles to qualify the use of
integrated bioimaging and biochemical markers
Chairs:
Wolfgang Koenig (Ulm,
Germany)
Peter Libby (Boston, MA, USA)
General Issues
|
| hour: |
|
|
abstract
page ref.: |
| 8.30-8.50 |
THE
FUTURE OF THE INTEGRATED APPROACH USING NONINVASIVE
IMAGING (MR, PET, CT) |
Zahi
A. Fayad (New York, NY, USA)
|
27 |
| 8.50-9.00 |
Discussion |
|
|
| 9.00-9.20 |
MOLECULAR
IMAGING: INFLAMMATION IN ATHEROSCLEROSIS |
Peter
Libby (Boston, MA, USA) |
28 |
| 9.20-9.30 |
Discussion |
|
|
|
| hour: |
|
|
abstract
page ref.: |
| 9.30-9.50 |
GENOMICS
IN ATHEROSCLEROSIS |
Maria
Benedetta Donati, Licia Iacoviello, Giovanni
de Gaetano
(Campobasso, Italy)
|
34 |
| 9.50-10.00 |
Discussion |
|
|
| 10.00-10.20 |
ISSUE
WITH MODELS OF INTEGRATION: “THE IMPROVE STUDY” |
Elena
Tremoli, Damiano Baldassarre on behalf
of the “IMPROVE Study Group”
(Milan, Italy) |
28 |
| 10.20-10.30 |
Discussion |
|
|
| 10.30-10.50 |
Coffee
Break |
|
|
Application
in Clinical Trials
Chairs:
Zahi
A. Fayad (New
York, NY, USA)
Ernst J. Schaefer (Boston, MA, USA)
|
| hour: |
|
|
abstract
page ref.: |
| 10.50-11.10 |
QUALIFICATION
OF INTEGRATED MEASURES FOR ADVANCEMENT OF NEW THERAPIES |
Stephen A. Williams (New London, CT, USA)
|
29 |
| 11.10-11.20 |
Discussion |
|
|
| 11.20-11.40 |
BIOMARKERS
IN CARDIOVASCULAR DRUG DEVELOPMENT. AN EU REGULATORY PERSPECTIVE |
Gonzalo
Calvo (Madrid, Spain) - Representative from
EMEA-CHMP |
29 |
| 11.40-11.50 |
Discussion |
|
|
| 11.50-12.10 |
REGULATORY
REQUIREMENTS FOR QUALIFICATION (US) |
Thomas
A. Marciniak (Silver Spring, MD, USA) - Representative
from FDA |
29 |
| 12.10-12.20 |
Discussion |
|
|
| 12.20-12.40 |
NEEDS
AND BENEFITS IN LARGE CLINICAL TRIALS |
Ernst
J. Schaefer (Boston, MA, USA) |
30 |
| 12.40-12.50 |
Discussion |
|
|
| 12.50-13.00 |
General
Discussion |
|
|
| 13.00 |
End
of the Session |
|
|
| 13.00-14.00 |
Lunch |
|
|
Session 6: PANEL DISCUSSION AND CONSENSUS ON
QUALIFICATION OF INTEGRATED BIOMARKERS (h. 14.00 -
18.20)
Purpose of this session:
to define the road to the qualification of integrated
biomarkers. Representatives from regulatory agencies,
scientific societies, pharma, imaging, and diagnostic
industries, CROs, and health organizations are invited
to discuss criteria for the qualification of integrated
biomarkers and to define the basis for consensus on the
validation of the integrated approach.
1st
part - Scientific Issues
|
| |
Chairs: |
|
Santica
M. Marcovina (Seattle, WA, USA)
Filippo Crea (Rome, Italy) |
| hour: |
|
|
abstract
page ref.: |
| 14.00-14.20 |
INTRODUCTION
TO THE DISCUSSION |
Filippo
Crea (Rome, Italy)
|
- |
| 14.20-16.00 |
PANEL DISCUSSION AND
DEVELOPMENT OF CONSENSUS |
QUALIFICATION
VERSUS VALIDATION OF BIOMARKERS
Mauro Panteghini (Milan, Italy)
CHARACTERISATION, VALIDATION AND EVALUATION
OF NOVEL DIAGNOSTIC ASSAYS
Thomas A. Metcalfe (Basel,
Switzerland)
Can
we agree that the level of evidence and the
technical performance required for qualification
are dependent on the context of the proposed
use?
INTEGRATED
- WHAT’S INTEGRATED?
Herbert Sucka (Hennigsdorf,
Germany)
MOLECULAR DIAGNOSTICS
Nicoletta Kahya (Eindhoven,
The Netherlands)
IMAGING BIOMARKERS FOR MOLECULAR MRI
Arne Hengerer (Erlangen, Germany) |
30
30
31
-
31 |
| 16.00-16.20 |
Coffee
Break |
|
|
|
2nd part- Critical Issues and Regulations
|
| |
Chairs |
|
Gonzalo
Calvo (Madrid, Spain)
Thomas A. Marciniak (Silver
Spring, MD, USA) |
|
| hour: |
|
|
abstract
page ref.: |
| 16.20-18.00 |
PANEL
DISCUSSION |
HUPO
HUMAN PLASMA PROTEOME PROJECT (HUPO PPP)
Gérard Siest (Nancy, France)
BOTTLENECKS TO THE DEVELOPMENT OF INTEGRATED
BIOMARKERS AND PROPOSED SOLUTIONS
Miriam Bayés (Barcelona,
Spain)
BOTTLENECKS IN THE DEVELOPMENT OF INTEGRATED BIOMARKERS
AND POTENTIAL SOLUTIONS
Pierre Braquet (Plaisir cedex,
France)
HOW CAN QUALIFICATION/VALIDATION PROJECTS IN TRANSLATIONAL
MEDICINE BE SUPPORTED MORE EFFECTIVELY?
Mario Plebani (Padua, Italy)
ROLE OF SCIENTIFIC SOCIETIES IN THE DEVELOPMENT
OF GUIDELINES FOR METHOD QUALIFICATION
Joseph P. McConnell (Rochester,
MN, USA)
|
32
34
32
33
33 |
| 18.00-18.20 |
General
discussion |
|
|
| 18.20-18.30 |
CONCLUDING REMARKS |
Rodolfo
Paoletti (Milan, Italy)
Santica M. Marcovina (Seattle,
WA, USA) |
29 |
| 18.30 |
End
of the Session |
|
|
|
|
SCIENTIFIC-ORGANIZING SECRETARIATS
Main
Office
Biomarkers 2007
Fondazione Giovanni Lorenzini
Medical Science Foundation
Via Appiani 7 - 20121 MILAN (ITALY)
Phone: + (39) 02 29006267
Fax + (39) 02 29007018
E-mail: biomarkers@lorenzinifoundation.org |
Branch
Office
Biomarkers 2007
Giovanni Lorenzini
Medical Foundation
6535 Fannin, M.S. A-601
Houston, Texas 77030 (USA)
Phone: (+1) 713 7970401
Fax: (+1) 713 7968853
E-mail: biomarkers@bcm.tmc.edu |
|
|
